Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A rare imaging case of bilateral plasmacytoma of the breast.
Eden JK, Borgen R, Haq R, Dobrashian R. Eden JK, et al. Among authors: haq r. BJR Case Rep. 2020 Sep 29;6(2):20190131. doi: 10.1259/bjrcr.20190131. eCollection 2020 Sep. BJR Case Rep. 2020. PMID: 33029381 Free PMC article.
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.
Tarantino G, Ricker CA, Wang A, Ge W, Aprati TJ, Huang AY, Madha S, Chen J, Shi Y, Glettig M, Feng CH, Frederick DT, Freeman S, Holovatska MM, Manos MP, Zimmer L, Rösch A, Zaremba A, Livingstone E, Jameson JC, Saghafian S, Lee A, Zhao K, Morris LGT, Reardon B, Park J, Elmarakeby HA, Schilling B, Giobbie-Hurder A, Vokes NI, Buchbinder EI, Flaherty KT, Haq R, Wu CJ, Boland GM, Hodi FS, Van Allen EM, Schadendorf D, Liu D. Tarantino G, et al. Among authors: haq r. Sci Adv. 2024 Nov 29;10(48):eadp4670. doi: 10.1126/sciadv.adp4670. Epub 2024 Nov 27. Sci Adv. 2024. PMID: 39602539 Free PMC article.
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.
Khaddour K, Haq R, Buchbinder EI, Liu D, Manos MP, Ott PA, Hodi FS, Insco ML. Khaddour K, et al. Among authors: haq r. Oncologist. 2024 Nov 6:oyae297. doi: 10.1093/oncolo/oyae297. Online ahead of print. Oncologist. 2024. PMID: 39504576 Free article.
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.
Seedor RS, Aplin AE, Bertolotto C, Carvajal RD, Deacon N, Doble K, Hamid O, Haq R, Kadosh M, Khan S, Kraska J, Lutzky J, McKean M, Montazeri K, Moser J, Onken M, Orloff M, Sacco JJ, Smalley K, Selig SM. Seedor RS, et al. Among authors: haq r. Pigment Cell Melanoma Res. 2025 Jan;38(1):e13205. doi: 10.1111/pcmr.13205. Epub 2024 Oct 9. Pigment Cell Melanoma Res. 2025. PMID: 39385554
Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement.
Sardana K, Srinivasan CR, Girdhar M, Hazarika N, Patel K, Rao N, Jain A, Sandhu J, Bansal S, Ghate S, Haq R, Agarwal DP. Sardana K, et al. Among authors: haq r. Expert Rev Clin Pharmacol. 2024 Sep 12:1-15. doi: 10.1080/17512433.2024.2401093. Online ahead of print. Expert Rev Clin Pharmacol. 2024. PMID: 39230196 Review.
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
Maloney AK, Giobbie-Hurder A, Katukota N, Fogarasi MC, Ott PA, Hodi FS, Sussman TA, Silk AW, Haq R, Liu D, Insco M, Buchbinder EI. Maloney AK, et al. Among authors: haq r. J Immunother Cancer. 2024 Aug 28;12(8):e009061. doi: 10.1136/jitc-2024-009061. J Immunother Cancer. 2024. PMID: 39209453 Free PMC article.
202 results